ArticleFrontiers in immunology2025
Histone-related gene WDR77 promotes tumor progression through cell cycle regulation in skin cutaneous melanoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Skin cutaneous melanoma (SKCM) is extremely malignant, leading to poor prognosis. Epigenetic dysregulation, particularly histone modifications, contributes to disease progression. However, effective histone-based prognostic biomarkers are still lacking in clinical practice. Methods: Transcriptomic data from TCGA-SKCM and five GEO datasets were analyzed. Ten machine learning algorithms were integrated to build 101 prognostic models. The optimal model, based on seven histone-related genes, showed the highest C-index and was validated in both training and validation cohorts. WDR77 was identified as the hub gene by random forest analysis. The expression of WDR77 was profiled in SKCM. Survival analysis, pathway enrichment analyses, single-cell and spatial transcriptomics were performed to investigate the role of WDR77 in SKCM. The therapeutic relevance of WDR77 was also investigated. In vitro experiments were conducted to validate the function of WDR77. Results: WDR77, a histone methylation factor working with PRMT5, was identified as a key candidate. WDR77 was significantly upregulated in SKCM and correlated with poor clinical outcomes. Pathway analysis showed that WDR77 was primarily associated with cell-cycle dysregulation. CDC20, a cell cycle factor, emerged as a key co-expressed gene. Patients with concurrent high expression of WDR77 and CDC20 had the worst survival outcomes. WDR77 was predominantly expressed in malignant cells across pan-cancer datasets and positively correlated with CDC20. Spatial transcriptomics confirmed their co-localization and co-upregulation in tumor regions. Functional experiments demonstrated that WDR77 promotes proliferation, migration, and cell cycle progression. Overexpression of WDR77 also increased CDC20 protein levels. Conclusion: WDR77 serves as both a prognostic biomarker and functional regulator in melanoma, highlighting its potential as a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.